Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-07-25Clinical Trial Update: Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy [Phase 2]
Phase 2 study evaluated diphenhydramine, lorazepam, and dexamethasone for chemotherapy-induced nausea and vomiting in pediatric patients. Th…
-
FDA approval · 2014-07-15FDA Approved: SANCUSO — Supplemental Application (Cumberland Pharmaceuticals Inc.)
The FDA approved Cumberland Pharmaceuticals' supplemental application for SANCUSO (granisetron), the transdermal antiemetic.
-
CLINICAL_TRIALS trial_result · 2014-04-04Clinical Trial Update: A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) [Phase 3]
Phase 3 clinical trial assessing the safety and efficacy of aprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatr…
-
CLINICAL_TRIALS trial_result · 2014-03-07Clinical Trial Update: Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy [Phase 3]
A Phase 3 trial evaluating Gabapentin to prevent chemotherapy-induced nausea and vomiting has completed, with results posted in 2014.
-
FDA approval · 2014-02-06FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Cipla USA Inc.)
The FDA approved a supplemental application for palonosetron hydrochloride submitted by Cipla USA Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-01-30Clinical Trial Update: Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial update evaluating fosaprepitant dimeglumine for chemotherapy-induced nausea and vomiting; the study was ter…
-
FDA approval · 2014-01-17FDA Approved: ONDANSETRON — Supplemental Application (ACTAVIS PHARMA, INC.)
FDA approved a supplemental application for ondansetron tablets from Actavis Pharma, Inc., adding a generic ondansetron tablet product to th…
-
CLINICAL_TRIALS trial_result · 2014-01-06Clinical Trial Update: Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis [Phase 3]
Phase 3 trial evaluating aprepitant to prevent cisplatin-induced delayed emesis has been terminated.
-
FDA approval · 2013-12-24FDA Approved: ONDANSETRON — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for ondansetron from Hospira, Inc., a generic product. The approval confirms the supplemental filing…
-
FDA approval · 2013-12-24FDA Approved: ONDANSETRON — Supplemental Application (Hospira, Inc.)
The FDA documents a supplemental application for ondansetron submitted by Hospira, Inc., indicating an FDA regulatory action on this product…
-
FDA approval · 2013-12-20FDA Approved: METOCLOPRAMIDE — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a generic metoclopramide hydrochloride tablet under an original application from Heritage Pharmaceuticals (d/b/a Avet Pharmaceu…
-
FDA approval · 2013-12-19FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's supplemental application for ondansetron hydrochloride, a generic antiemetic used to prevent nausea and vo…
-
CLINICAL_TRIALS trial_result · 2013-12-12Clinical Trial Update: A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012) [Phase 1]
Phase 1 trial evaluating the safety and tolerability of MK-0517 in healthy subjects. Results were posted in 2013.
-
FDA approval · 2013-12-10FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Onesource Specialty Pharma Limited)
FDA approved a supplemental application for ondansetron hydrochloride from Onesource Specialty Pharma Limited, indicating an approved modifi…
-
FDA label_change · 2013-11-19FDA Approved: SANCUSO — Supplemental Application (Cumberland Pharmaceuticals Inc.)
The FDA approved a Cumberland Pharmaceuticals supplemental application for SANCUSO (granisetron). The approval typically involves changes to…
-
FDA approval · 2013-10-07FDA Approved: ONDANSETRON — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for ondansetron submitted by Sun Pharmaceutical Industries (ANDA077557). Ondansetron is a generic an…
-
FDA approval · 2013-09-19FDA Approved: ONDANSETRON — Supplemental Application (West-Ward Pharmaceuticals Corp)
FDA approved a supplemental application for ondansetron from West-Ward Pharmaceuticals Corp under the ANDA.
-
FDA approval · 2013-09-19FDA Approved: METOCLOPRAMIDE — Supplemental Application (Teva Parenteral Medicines, Inc.)
FDA approved a supplemental application for METOCLOPRAMIDE from Teva Parenteral Medicines, Inc., for the approved generic product under ANDA…
-
FDA approval · 2013-09-19FDA Approved: ONDANSETRON — Supplemental Application (West-Ward Pharmaceuticals Corp)
The FDA approved a supplemental application for ondansetron from West-Ward Pharmaceuticals Corp under ANDA 076780, indicating an approved re…
-
FDA approval · 2013-08-30FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Onesource Specialty Pharma Limited)
FDA approved a supplemental application for ondansetron hydrochloride from Onesource Specialty Pharma Limited to permit the marketing of thi…
-
CLINICAL_TRIALS trial_result · 2013-08-26Clinical Trial Update: Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy [Phase 3]
A Phase 3 clinical trial compared acupressure wristbands to standard care for controlling chemotherapy-induced nausea and vomiting; the stud…
-
CLINICAL_TRIALS trial_result · 2013-08-22Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
This completed clinical trial evaluated the safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric pati…
-
CLINICAL_TRIALS trial_result · 2013-07-25Clinical Trial Update: Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC) [Phase 4]
Phase 4 trial evaluating the efficacy and safety of the Sancuso patch for chemotherapy-induced nausea and vomiting associated with highly em…
-
CLINICAL_TRIALS trial_result · 2013-07-24Clinical Trial Update: Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting [Phase 2]
A Phase 2 clinical trial evaluated whether yoga reduces chemotherapy-induced nausea and vomiting in patients with breast cancer, malignant n…
-
FDA approval · 2013-07-19FDA Approved: ONDANSETRON — Original Application (Fresenius Kabi USA, LLC)
FDA approved Fresenius Kabi USA, LLC's original application for a generic ondansetron hydrochloride product.